Szabadalmi Közlöny és Védjegyértesítő, 1988 (93. évfolyam, 1-4. melléklet)

1988 / 2. szám - dr. Farkas Erzsébet: Az első és második indikáció szabadalmazhatósága az Európai Szabadalmi Egyezmény alapján és a magyar szabadalmi törvény adta lehetőségek. Első rész

1988/6-SzKV

Melléklet

25

20. BGH: Benzolsulfonylharnstoff, G RU R 79, 652

(1977) ~

21. Sitosteryl glycosides, ПС 14(2), 283 (1983)

22. lan de Minvielle-Devaux, IIC 14(2), 286 (1983)

23. Pyrrolidine Derivatives, O.J.EPO 164 (1984)

24. Guidelines for Examination in the EPO Art.10(2) Part C Chapter IV paragraph 4.2., O.J.EPO 188 (1984)

25. Vogt, GRUR 68, 317(1966)

26. G.Klöpsch, IIC 13(4), 457 (1982)

27. BGH: Selective Herbizide, GRUR 78,633 (1976)

28. P.Mathély: Le droit français des brevets d'invention (Paris, Jour.Not.et.Av. 1974)

a) 508,509; b) 97, 99, 102; c) 130

29. P.Mathély: Le droit européen des brevets d'invention 116 (Paris, Jour.Notet.Av. 1978)

30. К.Bruchhausen, GRUR 79, 297, 302 (1977)

31. R.Singer,Mitt.65,2 (1974) ésGRUR Int. 62 (1974)

32. Minutes of the Munich Diplomatie Conference for the Setting up of a European System for the Grant of Patents, Paragraph 57:

The Chairman replied to the Yugoslav delegation and said that, in his opinion, the aim in paragraph 5 was to make clear that a known substance (or a known composition) which, since it formed part of the state of the art, was no longer patentable, nevertheless could be patented for the first use in a method of treatment of the human or animal body by surgery or therapy, however, a further patent could not be granted if a second possible use were found for the same substance, irrespective of whether the human or animal body was to be treated with it.

33. B.Hansen, GRUR 79,20 (1977)

34. P. Krasa, GRUR 79, 481 (1977)

35. H.A.Zutrauen, GRUR Int. 225 (1977)

36. O.Bossung, Mitt, 65, 101, 121, 126, 141 (1974)

37. G.Klöpsch, GRUR 81, 284(1979)

38. E.Frhr. von Pechman, Mitt. 68, 106 (1977)

39. Dost; European Patent Law, A—6—8

40. K.Nastelski: Festschrift für Wilde, 113 (1970)

41. M.Meikowski, GRUR 79, 203(1977)

42. P.Devant, R.PIasseraud, R.Gumann, H.Jacquelin, M.Lemoine: Les Brevets d'invention 106, 111 (Paris, Dalloz, 1971)

43. M.de Haas: Brevet et médicament en droit français et en droit européen. No 496, 227 (Paris, Libraries Techniques, 1981)

44. Armengaud, Doc.Senat, No 46, 19 (1967—1968)

45. J.Am.Med.Assoc. 208, 1168 (1969)

46. The Lancet II 1211 (1978)

47. K.Bruchhausen in 7 Benkard: Kommentar zum Pate ntgesetz

a) note 76 to Art 1 PatG

b) note 75 to Art 1 Pat G

48. H.Bock in Benkard: Patentgesetz, Gebrauchmustergesetz 242 (6th ed.)

49. R.Lemay, Droit SocialJL 7 (1971)

50. J.Azéma: Les brevets et les marques pharmaceutiques (ed. Institut de pharmacie industrielle de Lyon,1972)

51. H.Müller, GRUR 85, 471 (1983)

52. W.Trüstedt, GRUR 85, 478 (1983)

53. V.Vossius und O.Vossius, GRUR 85, 483 (1983)

54. E.Steger, GRUR 85, 474 (1983)

55. H.Suchy, IIC 13(4), 471 (1982)

56. Ticlopidine, Decision of the Patent Office, London, IIC 14(5), 661 (1983)

57. Patent Act 1977 Section 2(6):

In the case of an invention consisting of a substance or composition for use in a method of treatment of the human or animal body by surgery or therapy or of diagnosis practised on the human or animal body, the fact, that the substance or composition forms part of the state of the art shall not prevent the invention from being taken to be new if the use of the substance or composition in any such method does not form part of the state of the art.

58. Cytostatic Combination, Decision of the Technical Board of Appeal 3.3.1 EPO, O.J.EPO 372 (1983)

59. A.White, EIPR 39 (1984)

60. Nimodipin, Final decision of the United Kingdom Patent Office, O.J.EPO 233 (1984)

61. Nimodipin, Decision of the Technical Board of Appeal 3.3.1 EPO, O.J.EPO 266 (1983)

62. Hydropiridine, Important decision of the BGH, O.J.EPO 26 (1984)

63. G.Klöpsch, GRUR 85, 733 (1983)

64. M.de Haas, Industrial Property 119 (1984)

65. E.Schraufstatter: Die Entwicklung eines Arzneimittels aus der Sicht des Chemikers in „Der Weg der neuen Arzneimittel" (W.Trummert, J.F. Lehmanns Verlag München, 1963) 2